Tables
Table I - Oral Estrogens
| Drug | Lower Dose | Standard Dose | Higher Dose | ||
|---|---|---|---|---|---|
| Conjugated equine estrogen (Premarin) | 0.3mg | 0.625mg qd | 0.9mg | 1.25mg | 2.5mg |
| Micronized estradiol (Estrace) | 0.5mg | 1.0mg qd or 0.5mg bid | -- | 2.0mg | -- |
| Estrone (Ogen) | -- | 0.625mg qd | -- | 1.25mg | 2.5mg |
| Estrone (Ortho-est) | -- | 0.625mg qd | -- | 1.25mg | -- |
Table II - Estrogen Patches (Transdermal Estradiol
| Type of Drug Interval | Lower Dose | Usual Minimum Dose | Higher Dose | Patch Change Interval |
|---|---|---|---|---|
| Transdermal estradiol reservoir system (Estroderm) | -- | 0.05mg | 0.10mg | Every 3 1/2 days |
| Transdermal estradiol matrix system (Vivelle) | 0.0375mg | 0.05mg | 0.075-0.10mg | Every 3 1/2 days |
| Transdermal estradiol matrix system (Climara) | -- | 0.05mg | 0.10mg | Weekly |
Table III - Hormone Replacement Therapy
| Benefit | Risk |
|---|---|
| Relief of vasomotor symptoms. | Acceleration of an already existing breast cancer. |
| Prevention of postmenopausal osteoporosis, fractures. | Endometrial cancer risk increases 5- to 10-fold if estrogen is unopposed. |
| Reduction of cardiovascular risk. | PMS-like side effects with progestin-estrogen program. |
| Reversal of genitourinary atrophy. | Increased incidence of gallbladder disease. |
| Possible improvement in mood, energy, and recent memory |
Cite this: Update on Hormone Replacement: Sorting Out the Options for Preventing Coronary Artery Disease and Osteoporosis - Medscape - Jun 29, 1996.
Comments